Elicio Therapeutics, Inc. Operating Lease Cost
Elicio Therapeutics, Inc. (ELTX) reported Operating Lease Cost of $27.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2023-05-10
- Elicio Therapeutics, Inc. operating lease, cost for the quarter ending 2023-03-31 was $27.00K, a 93.46% decline year-over-year.
- Elicio Therapeutics, Inc. operating lease, cost for the quarter ending 2022-12-31 was $302.00K, a 32.46% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, cost for the quarter ending 2022-09-30 was $301.00K, a 7.38% decline year-over-year.
- Elicio Therapeutics, Inc. operating lease, cost for the quarter ending 2022-06-30 was $302.00K, a 4.73% decline year-over-year.
- Elicio Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.32M, a 15.32% increase from fiscal 2021.
- Elicio Therapeutics, Inc. operating lease, cost for fiscal 2021 was $1.14M, a 3.91% increase from fiscal 2020.
- Elicio Therapeutics, Inc. operating lease, cost for fiscal 2020 was $1.10M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $27.00K 10-Q · filed 2023-05-10 | $329.00K derived: sum of 2 quarters · filed 2023-05-10 | $630.00K derived: sum of 3 quarters · filed 2023-05-10 | $932.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $603.00K derived: sum of 2 quarters · filed 2023-03-17 | $905.00K derived: sum of 3 quarters · filed 2023-03-17 | $1.32M 10-K · filed 2023-03-17 |
| 2022-09-30 | $301.00K 10-Q · filed 2022-11-14 | $603.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.01M 10-Q · filed 2022-11-14 | $1.24M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $302.00K 10-Q · filed 2022-08-15 | $714.00K 10-Q · filed 2022-08-15 | $943.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.27M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $413.00K 10-Q · filed 2023-05-10 | $641.00K derived: sum of 2 quarters · filed 2023-05-10 | $966.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.28M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $553.00K derived: sum of 2 quarters · filed 2023-03-17 | $870.00K derived: sum of 3 quarters · filed 2023-03-17 | $1.14M 10-K · filed 2023-03-17 |
| 2021-09-30 | $325.00K 10-Q · filed 2022-11-14 | $642.00K derived: sum of 2 quarters · filed 2022-11-14 | $914.00K 10-Q · filed 2022-11-14 | $1.11M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $317.00K 10-Q · filed 2022-08-15 | $590.00K 10-Q · filed 2022-08-15 | $783.00K derived: sum of 3 quarters · filed 2022-08-15 | $1.11M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $273.00K 10-Q · filed 2022-05-16 | $466.00K derived: sum of 2 quarters · filed 2022-05-16 | $791.00K derived: sum of 3 quarters · filed 2022-05-16 | $1.08M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $518.00K derived: sum of 2 quarters · filed 2022-03-30 | $811.00K derived: sum of 3 quarters · filed 2022-03-30 | $1.10M 10-K · filed 2022-03-30 |
| 2020-09-30 | $325.00K 10-Q · filed 2021-11-12 | $618.00K derived: sum of 2 quarters · filed 2021-11-12 | $906.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $293.00K 10-Q · filed 2021-08-12 | $581.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $288.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |